Compounders Research Compare

Edesa Biotech, Inc.(EDSA)

Biotechnology · Markham, ON

$3.87-0.04 (-1.15%)

Delayed quote: Oct 6, 2026, 10:38 AM EDT

About Edesa Biotech, Inc.

Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.

Markham, ON

17 employees

www.edesabiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Pardeep Nijhawan

View full financials

Edesa Biotech (EDSA) EV/EBITDA: History & Chart | TGMCharts

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T14:51:50.683Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:51:50.683Z.

Quote observation: 2026-10-06T14:38:49.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 37,232,395
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 10,332,520
TTM operating EBITDA · period ending 2026-06-30: -14,525,331

FMP input reference: 4a3a0e03002c1ec33ed026058caacdcc2374dd3411b27b5cd001974e391cfa1f

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

EDSA EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

EDSA Competitors' EV/EBITDA Ratio

Edesa Biotech, Inc.

Current

Market Cap

$37.23M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

iTonic Holdings Ltd.

Market Cap

$37.15M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DocGo Inc.

Market Cap

$36.48M

EV/EBITDA Ratio

N/A

TTM Avg

6.76x

3Y Avg

19.14x

5Y Avg

45.56x

Elicio Therapeutics, Inc.

Market Cap

$36.13M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Harvard Bioscience, Inc.

Market Cap

$38.52M

EV/EBITDA Ratio

10.53x

TTM Avg

9.64x

3Y Avg

45.33x

5Y Avg

52.62x

Incannex Healthcare Limited

Market Cap

$38.71M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Accuray Incorporated

Market Cap

$35.70M

EV/EBITDA Ratio

N/A

TTM Avg

25.79x

3Y Avg

51.85x

5Y Avg

38.84x

Nephros, Inc.

Market Cap

$39.63M

EV/EBITDA Ratio

20.28x

TTM Avg

31.88x

3Y Avg

41.18x

5Y Avg

41.18x

BriaCell Therapeutics Corp.

Market Cap

$34.80M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Elutia Inc

Market Cap

$34.48M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Edesa Biotech, Inc. (EDSA)	$37.23M	N/A	N/A	N/A	N/A
iTonic Holdings Ltd. (ITOC)vs ›	$37.15M	N/A	N/A	N/A	N/A
DocGo Inc. (DCGO)vs ›	$36.48M	N/A	6.76x	19.14x	45.56x
Elicio Therapeutics, Inc. (ELTX)vs ›	$36.13M	N/A	N/A	N/A	N/A
Harvard Bioscience, Inc. (HBIO)vs ›	$38.52M	10.53x	9.64x	45.33x	52.62x
Incannex Healthcare Limited (IXHL)vs ›	$38.71M	N/A	N/A	N/A	N/A
Accuray Incorporated (ARAY)vs ›	$35.70M	N/A	25.79x	51.85x	38.84x
Nephros, Inc. (NEPH)vs ›	$39.63M	20.28x	31.88x	41.18x	41.18x
BriaCell Therapeutics Corp. (BCTX)vs ›	$34.80M	N/A	N/A	N/A	N/A
Elutia Inc (ELUT)vs ›	$34.48M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics